Joaquín Mosquera

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 433 citations

Second-line Treatment, Oncology, Metronomic Therapy +9

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba et al. · New England Journal of Medicine · 2023 · 397 citations · Full text

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Ernest Nadal, Delvys Rodríguez‐Abreu, Marta Simó et al. · Journal of Clinical Oncology · 2023 · 93 citations · Full text

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

Ma Carmen Areses Manrique, Joaquín Mosquera, Jorge García et al. · Translational Lung Cancer Research · 2018 · 62 citations · Full text

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

Mariano Provencio-Pulla, Ernest Nadal, J.L. González-Larriba et al. · Journal of Clinical Oncology · 2022 · 61 citations

Surgical Oncology, Oncology, Pcr Rate +13